Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference